Early Post-Transplant Oliguria and Rising Creatinine After Kidney Transplant
A 39-year-old woman with IgA nephropathy receives a living-related kidney transplant from her sister. The surgery is uncomplicated, with a single renal artery and vein and a ureteroneocystostomy over a double-J stent. Intraoperative urine output is brisk. On postoperative day 1, urine output falls to 15 mL/h, serum creatinine rises from 1.4 to 2.6 mg/dL, and the patient reports pain over the graft site. Blood pressure is 158/92 mmHg, heart rate 96/min, temperature 37.4°C. Tacrolimus trough is 6 ng/mL, and she is on mycophenolate and prednisone. Doppler ultrasound shows a patent renal artery and vein with normal resistive indices and no perinephric collection. The bladder is not distended.
1. Construct a differential diagnosis for early oliguria and rising creatinine in this patient and explain how the ultrasound findings modify your priorities.
Read the worked answer
The differential includes delayed graft function/acute tubular necrosis, acute rejection (cellular or antibody-mediated), calcineurin inhibitor toxicity, urinary obstruction or urine leak, vascular thrombosis, hypovolemia, and infection/sepsis. The Doppler ultrasound is reassuring against large-vessel thrombosis and shows no obstruction or collection, which lowers the priority of vascular and obstructive causes but does not exclude them completely. The patient has graft pain and mild tachycardia, which raise concern for rejection or infection, but pain can also reflect capsular stretch from edema.
Key reasoning: brisk intraoperative urine output followed by oliguria suggests a new insult rather than primary nonfunction. A tacrolimus trough of 6 ng/mL is within or below typical target range, making CNI toxicity less likely as the sole cause. The absence of hydronephrosis argues against obstruction, but a non-distended bladder and patent vessels do not rule out early acute rejection or ATN. The next steps should include volume assessment, urinalysis and urine culture, CMV/BK viral load if indicated, donor-specific antibody testing, and consideration of graft biopsy if oliguria persists.
2. If a biopsy shows Banff borderline changes with mild tubulitis and no evidence of antibody-mediated rejection, how would you manage immunosuppression and monitoring?
Read the worked answer
Borderline changes (suspicious for acute T-cell–mediated rejection) with mild tubulitis but no intimal arteritis are a gray zone. Management depends on clinical context: if there is graft dysfunction, many centers treat with pulse corticosteroids (e.g., methylprednisolone 250–500 mg daily for 3 days) and optimize maintenance immunosuppression. If renal function is stable, some centers observe with repeat biopsy rather than treat, because overtreatment increases infection risk. In this patient with rising creatinine and oliguria, treatment is reasonable.
Additional steps: (1) Check tacrolimus trough and adjust to target (often 8–12 ng/mL early post-transplant depending on protocol); the current 6 ng/mL may be subtherapeutic. (2) Review mycophenolate exposure and adherence. (3) Test for donor-specific antibodies to exclude subclinical antibody-mediated rejection, since borderline changes can coexist with DSA. (4) Repeat biopsy if function does not improve within 1–2 weeks. (5) Monitor for infection (BK virus, CMV) because increased immunosuppression raises risk. The judgment is to treat when dysfunction is present while avoiding escalation in stable patients.